Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models

Because of its role in mediating both B cell and Fc receptor signaling, Bruton’s tyrosine kinase (BTK) is a promising target for the treatment of autoimmune diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Evobrutinib is a novel, highly selective, irreversible BTK i...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Immunol
Autors principals: Haselmayer, Philipp, Camps, Montserrat, Liu-Bujalski, Lesley, Nguyen, Ngan, Morandi, Federica, Head, Jared, O’Mahony, Alison, Zimmerli, Simone C., Bruns, Lisa, Bender, Andrew T., Schroeder, Patricia, Grenningloh, Roland
Format: Artigo
Idioma:Inglês
Publicat: AAI 2019
Matèries:
Autoimmunity
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6500888/
https://ncbi.nlm.nih.gov/pubmed/30988116
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4049/jimmunol.1800583
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars